基于模型的Meta分析方法在抗糖尿病药疗效评价中的应用现状  

Application Status of Model-based Meta-analysis in Evaluation of Efficacy of Hypoglycemic Drugs

作　　者：闫开成 蔡芸[1] 王睿[1] YAN Kaicheng;CAI Yun;WANG Rui(Dept. of Pharmacy, Medical Care Center, China PLA General Hospital, Beijing 100853, China)

机构地区：[1]中国人民解放军总医院医疗保障中心药剂科,北京100853

出　　处：《中国医院用药评价与分析》2020年第8期1020-1024,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：十三五重大新药创制国家科技重大专项(No.2018ZX09201013)。

摘　　要：基于模型的Meta分析(model-based meta-analysis,MBMA)是一个定量的药理学方法,其基于既往临床研究数据,建立药效学模型和统计学模型,并引入协变量来预测药物疗效。MBMA可以为2型糖尿病治疗药物的选择提供有效方法,建立模型对各类抗糖尿病药在血糖控制、体重变化和低血糖风险等方面进行比较分析,对不同给药剂量和治疗间期进行模拟和预测,为临床医师针对不同患者进行个体化治疗提供依据。Model-based meta-analysis(MBMA)is a type of quantitative pharmacological method.Based on the previous clinical research data,pharmacodynamic model and statistical model are established,and covariates are introduced to predict the drug efficacy.MBMA can provide an effective method for the selection of treatment drugs for type 2 diabetes mellitus,establish a model to compare and analyze various hypoglycemic drugs in the aspects of blood glucose control,weight change and hypoglycemia risk,simulate and predict different dosage and treatment interval,so as to improve the basis for specialists to carry out individualized treatment in different patients.

关 键 词：基于模型的Meta分析 药效学模型 2型糖尿病 抗糖尿病药 

分 类 号：R977.15[医药卫生—药品]